Skip to main content

Market Access Monitor

Service of monitoring key reimbursement and HTA developments for medical devices, in-vitro diagnostic tests, and digital technologies in Europe and globally

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Funding for AI Life Sciences Accelerator Mission in the UK

29 Nov 2023

In late October 2023, the UK Government announced £100 million funding for the “AI Life Sciences Accelerator Mission” to advance and expand the use of AI in life sciences and tackle the country’s major health challenges. The investment will be targeted towards areas where rapid deployment of AI has the most significant potential to create transformational breakthroughs in treatments for previously incurable diseases. AI Mission will help drive forward eight critical healthcare missions outlined by Life Sciences Vision by exploring how AI could address them. 

The funding will target opportunities to deploy AI in clinical settings and improve health outcomes across various conditions. The government will invite proposals bringing together academia, industry, and clinicians to develop innovative solutions.

See the full details here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.